Stephen Sharp
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1508943515
Payments from drug & device makers
Across 4,278 payments — averaging $6065.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10M
- AstraZeneca$4.1M
- Modernatx, Inc.$3.8M
- Merck$2.4M
- Seqirus USA Inc$1.2M
- Johnson & Johnson$973K
- plus $3.4M from 23 others
Across 15 payments — averaging $1414.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$18K
- Eli Lilly$2K
- Teva Pharmaceuticals USA, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 341 | $9,997,438 |
| AstraZeneca | 9 | $4,144,187 |
| Modernatx, Inc. | 2,066 | $3,757,613 |
| Merck | 26 | $2,421,206 |
| Seqirus USA Inc | 792 | $1,230,304 |
| Johnson & Johnson | 39 | $973,276 |
| Novavax Inc | 121 | $621,474 |
| Boehringer Ingelheim | 59 | $608,520 |
| Emergent Biosolutions Inc. | 540 | $473,468 |
| Eli Lilly | 13 | $462,061 |
| Hoffmann-la Roche Limited | 20 | $450,324 |
| Genentech, Inc. | 35 | $226,408 |
| Braintree Laboratories, Inc. | 34 | $161,841 |
| Roche Diabetes Care, Inc. | 4 | $103,272 |
| Rapid Pathogen Screening, Inc. | 5 | $60,220 |
| Sanofi US Services Inc. | 13 | $53,748 |
| Teva Pharmaceuticals USA, Inc. | 15 | $39,062 |
| AMAG Pharmaceuticals, Inc. | 4 | $37,942 |
| Sanofi Pasteur Inc. | 17 | $33,537 |
| Boehringer Ingelheim International GmbH | 102 | $27,950 |
| Janssen Research & Development, LLC | 9 | $26,560 |
| F. Hoffmann-la Roche AG | 1 | $12,503 |
| Phathom Pharmaceuticals, Inc. | 2 | $6,620 |
| GSK | 2 | $6,500 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $6,000 |
| Sunovion Pharmaceuticals Inc. | 2 | $3,815 |
| Novartis | 1 | $1,000 |
| Novo Nordisk AS | 3 | $55 |
| Medline Industries LP | 1 | $16 |
How this compares
$25,946,921 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Other endocrinology, diabetes & metabolism in Nashville
- Kathryn DahirNashville$11M
- Craig WierumNashville$1.7M
- Terri JerkinsNashville$1.2M
- Shichun BaoNashville$735K
- Michael MayNashville$689K
- Michael CarlsonNashville$381K
- Rodney SnowNashville$188K
- Kevin NiswenderNashville$100K
- Howard BaumNashville$81K
- Annis MarneyNashville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.